Dr. Scott M. Rocklage is an expert in strategic healthcare management and leadership, possessing more than 20 years of experience in both the management and clinical aspects of medicine and drug development. He currently works at 5AM Ventures, as a Managing Partner. He joined the firm as a venture partner in 2003. Together with the company, Dr. Scott M. Rocklage specializes in drug development and product discovery.
His leadership skills have led to the FDA-approval of 3 new drug applications successfully, as well as entering multiple drug entries into clinical trials. Dr. Rocklage has published more than 100 works reviewed by industry peers and has a hand in the development of more than 30 patents.
As a venture capital firm, 5AM Ventures specializes in early stage companies dealing with life sciences, biopharmaceutical technologies, and medical research and development. The firm has specialized in the process of company formation, hence the emphasis on early stage ventures. 5AM Ventures implements a strategy to invest in new businesses or entities with validated later-stage technologies. The firm has a diversified portfolio of investments in sectors such as corporate spin-offs, platform technologies, and products with a short development cycle.
Dr. Rocklage holds a Bachelor of Science degree in Chemistry from the University of California-Berkeley. He also attended the Massachusetts Institute of Technology from where he earned a Ph.D. in Chemistry and more information click here.
While at MIT, he had the pleasure of conducting his research in the laboratory of the 2005 winner of the Nobel Prize in Chemistry, Richard R. Schrock.
Dr. Rocklage has extensive experience in medical research and development, as well as healthcare management working for companies such as Catalytica, Cubist Pharmaceuticals, EntreMed, Ilypsa, Nycomed Salutar, Nycomed Interventional, and Relypsa and contact him.
Over the years, he has been in control of highly successful teams that have gathered more than $500 million in seed capital and funding. Dr. Rocklage is also responsible for the successful IPO and follow-up financing for Cubist Pharmaceuticals.
Board Memberships and Nonprofit Donations
He currently serves as a board member of Epirus Biopharmaceuticals, Pulmatrix, Rennovia, and the Whitehead Institute for Biomedical Research. Dr. Rocklage is also an active contributor to the Sudbury Valley Trustees and the U.S Lacrosse Foundation.
More visit: https://www.tumblr.com/blog/scottrocklage